X4 Pharmaceuticals (NASDAQ:XFOR) Cut to “Hold” at Zacks Research

Zacks Research lowered shares of X4 Pharmaceuticals (NASDAQ:XFOR) from a strong-buy rating to a hold rating in a research note published on Wednesday,Zacks.com reports.

A number of other brokerages have also issued reports on XFOR. Stifel Nicolaus set a $7.50 target price on X4 Pharmaceuticals in a research report on Wednesday, November 5th. Wall Street Zen upgraded X4 Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Saturday, November 22nd. Weiss Ratings restated a “sell (d-)” rating on shares of X4 Pharmaceuticals in a report on Monday. Finally, HC Wainwright set a $3.50 target price on X4 Pharmaceuticals and gave the company a “buy” rating in a research note on Wednesday, August 13th. Three investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, X4 Pharmaceuticals has a consensus rating of “Hold” and an average price target of $33.67.

X4 Pharmaceuticals Trading Up 1.1%

NASDAQ XFOR opened at $3.68 on Wednesday. The stock has a market cap of $321.78 million, a P/E ratio of -0.36 and a beta of 0.51. The company’s fifty day simple moving average is $3.52 and its 200-day simple moving average is $2.98. The company has a current ratio of 5.65, a quick ratio of 5.48 and a debt-to-equity ratio of 1.23. X4 Pharmaceuticals has a 52 week low of $1.35 and a 52 week high of $26.83.

X4 Pharmaceuticals (NASDAQ:XFOR) last released its quarterly earnings results on Wednesday, November 5th. The company reported ($0.69) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.79) by $0.10. X4 Pharmaceuticals had a negative net margin of 279.86% and a negative return on equity of 343.67%. The business had revenue of $1.77 million during the quarter, compared to analyst estimates of $2.05 million. Equities research analysts predict that X4 Pharmaceuticals will post -0.68 EPS for the current fiscal year.

Insider Buying and Selling

In other news, Chairman Adam R. Craig bought 86,206 shares of X4 Pharmaceuticals stock in a transaction on Thursday, October 23rd. The shares were bought at an average price of $2.90 per share, with a total value of $249,997.40. Following the acquisition, the chairman directly owned 376,087 shares in the company, valued at approximately $1,090,652.30. This represents a 29.74% increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. 2.37% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On X4 Pharmaceuticals

Several institutional investors and hedge funds have recently made changes to their positions in the company. Charles Schwab Investment Management Inc. boosted its holdings in X4 Pharmaceuticals by 9.9% in the first quarter. Charles Schwab Investment Management Inc. now owns 481,528 shares of the company’s stock worth $114,000 after purchasing an additional 43,320 shares during the period. Kingdon Capital Management L.L.C. raised its holdings in shares of X4 Pharmaceuticals by 41.8% during the first quarter. Kingdon Capital Management L.L.C. now owns 7,000,000 shares of the company’s stock worth $1,655,000 after purchasing an additional 2,063,000 shares during the period. Pale Fire Capital SE lifted its position in shares of X4 Pharmaceuticals by 45.2% in the 1st quarter. Pale Fire Capital SE now owns 2,035,362 shares of the company’s stock worth $481,000 after buying an additional 633,398 shares during the last quarter. Nantahala Capital Management LLC bought a new position in shares of X4 Pharmaceuticals in the 3rd quarter worth about $7,621,000. Finally, Deep Track Capital LP acquired a new position in shares of X4 Pharmaceuticals in the 3rd quarter valued at about $3,839,000. 72.03% of the stock is owned by institutional investors and hedge funds.

X4 Pharmaceuticals Company Profile

X4 Pharmaceuticals, Inc, a late-stage clinical biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases. Its lead product candidate is mavorixafor, a small molecule inhibitor of the chemokine receptor C-X-C chemokine receptor type 4 (CXCR4), which is in Phase III clinical trial for the treatment of patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome; and Phase II clinical trial to treat congenital, idiopathic, or cyclic neutropenia.